Key terms
About VIR
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VIR news
Today
9:02am ET
Vir Biotechnology Announces CFO Departure and Board Expansion
Apr 04
4:16pm ET
Vir Biotechnology CEO sells 72,995 common shares
Mar 11
12:46am ET
Buy Rating Affirmed for Vir Biotechnology on Promising HDV and HBV Programs and Strategic Market Positioning
Mar 05
8:36am ET
Vir Biotechnology completes Phase 2 SOLSTICE clinical trial ahead of schedule
Feb 26
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Feb 26
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Feb 25
11:29pm ET
Optimistic Outlook for Vir Biotechnology’s Clinical Programs and Financial Position Reinforces Buy Rating
Feb 23
11:25am ET
Strong Buy Rating for Vir Biotechnology on Promising Hepatitis Pipeline and Market Leadership Potential
Feb 23
7:16am ET
Maintaining Hold on Vir Biotechnology Amid Revenue Decline and Strategic Pivot
Feb 23
7:15am ET
Optimistic Buy Rating on Vir Biotechnology Amidst Advancing HDV and HBV Programs and Upcoming Clinical Catalysts
Feb 23
3:05am ET
Barclays Issues a Buy Rating on Vir Biotechnology (VIR)
Feb 23
12:16am ET
Buy Rating Affirmed for Vir Biotechnology on Promising Hepatitis Drug Pipeline and Market Potential
Feb 22
4:24pm ET
Vir Biotechnology Ends Influenza Deal with GlaxoSmithKline
Feb 20
4:43pm ET
Vir Biotechnology Announces Executive Leadership Transition
Feb 20
4:34pm ET
Vir Biotechnology Chief Medical Officer to step down
Feb 16
11:22am ET
Biotech Alert: Searches spiking for these stocks today
Feb 14
6:06am ET
Vir Biotechnology price target raised to $110 from $85 at H.C. Wainwright
Jan 23
6:04am ET
Vir Biotechnology price target lowered to $85 from $95 at H.C. Wainwright
No recent press releases are available for VIR
VIR Financials
Key terms
Ad Feedback
VIR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VIR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
